Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABI-007 and Carboplatin in Unresectable Stage IV Melanoma
NCT00404235Phase 2Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Oct 2006
- Primary completion
- Dec 2008
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of nab-paclitaxel in melanoma, sponsored by Cancer and Leukemia Group B. Primary endpoint: Objective Response Rate at 2 years. Started Oct 2006; status: completed.
02
Drugs
nab-paclitaxel
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00404235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00404235.